Company Profile
Gubra A/S, a disease-agnostic techbio company focuses on the peptide-based drug discovery and preclinical contract research services globally. Its business is organized into three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract R&D services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry
Various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinformatics, and 2D and 3D histology with artificial intelligence pathology. It also has a portfolio strategy of potential drug candidates in the form of upfront payments, research payments, milestone payments, and royalties
Investments targeting as sets promoting the green transition. The company has partnership and collaboration with Boehringer Ingelheim for the treatment of obesity. Its portfolio also includes Camurus' FluidCrystal technology to develop a therapy for hypoparathyroidism, and Amylyx Pharmaceuticals to develop a GLP-1 receptor antagonist for post-bariatric hypoglycemia and rare diseases. Incorporated in 2008, Gubra is headquartered in Horsholm, Denmark.